0.45
-0.0315(-6.58%)
Currency In USD
| Previous Close | 0.48 |
| Open | 0.46 |
| Day High | 0.48 |
| Day Low | 0.43 |
| 52-Week High | 3.31 |
| 52-Week Low | 0.42 |
| Volume | 65,890 |
| Average Volume | 234,333 |
| Market Cap | 2.12M |
| PE | -0.09 |
| EPS | -4.8 |
| Moving Average 50 Days | 0.66 |
| Moving Average 200 Days | 1.23 |
| Change | -0.03 |
If you invested $1000 in Processa Pharmaceuticals, Inc. (PCSA) 10 years ago, it would be worth $1.88 as of March 14, 2025 at a share price of $0.448. Whereas If you bought $1000 worth of Processa Pharmaceuticals, Inc. (PCSA) shares 5 years ago, it would be worth $2.29 as of March 14, 2025 at a share price of $0.448.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference
GlobeNewswire Inc.
Feb 07, 2025 1:00 PM GMT
HANOVER, Md., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation cancer therapies with improved efficacy and s
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
Jan 30, 2025 10:17 PM GMT
HANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved ef
Processa Pharmaceuticals Reports Third Quarter Business Highlights and Financial Results
GlobeNewswire Inc.
Oct 30, 2024 8:15 PM GMT
First patient dosed in Phase 2 clinical trial with NGC-Cap for metastatic breast cancer Positive data from preclinical studies support NGC-Iri’s ability to deliver more SN-38 to tumors compared with either irinotecan or Onivyde® HANOVER, Md., Oct.